Voglixta 0.3MG Tab

Tablet

Management of type 2 diabetes mellitus to reduce post‑prandial (after-meal) blood glucose; used alone or with other antidiabetic medicines along with diet and exercise.

Voglibose is an alpha‑glucosidase inhibitor that delays breakdown and absorption of carbohydrates in the intestine. This reduces the rise in blood glucose after meals and helps improve overall glycaemic control.

Oral tablet. Typically taken just before or with the first bite of each main meal, as prescribed by the doctor. Swallow with water; do not skip meals after taking a dose. Follow diabetic diet and exercise advice.

Flatulence, abdominal pain, diarrhoea, bloating, nausea

Use with caution in patients with intestinal disorders (e.g., inflammatory bowel disease, colonic ulceration, partial intestinal obstruction), severe liver disease, or renal impairment. Risk of hypoglycaemia increases when combined with insulin or sulfonylureas—treat low sugar with glucose (dextrose), not sucrose, as carbohydrate absorption is delayed. Not for type 1 diabetes or diabetic ketoacidosis. Monitor blood glucose and HbA1c regularly.

Insulin, sulfonylureas (e.g., glimepiride/gliclazide), other antidiabetics (additive effect), intestinal adsorbents and digestive enzyme preparations (may reduce effect), corticosteroids and thyroid hormones (may raise glucose), alcohol (may increase hypoglycaemia risk when used with other antidiabetics)

Store below 25°C in a cool, dry place. Protect from moisture and direct light. Keep out of reach of children.

Vobose 0.3 Tablet, Voglib 0.3 Tablet, Volibo 0.3 Tablet, Voglitor 0.3 Tablet, Emgluc 0.3 Tablet